Literature DB >> 15128881

Diagnostic utility and safety of transjugular kidney biopsy in the obese patient.

Derek M Fine1, Aravind Arepally, Lawrence V Hofmann, Steven G Mankowitz, Mohamed G Atta.   

Abstract

BACKGROUND: The obese patient may be potentially at high risk for traditional percutaneous ultrasound-guided biopsy. The utility of transjugular kidney biopsy (TJKB) in this group of patients has not been established.
METHODS: We conducted a retrospective analysis of 37 obese patients who underwent TJKB at our centre. The kidney was approached via the right renal vein in 31 patients. Under fluoroscopy, core biopsies were obtained from the lower pole with a 19G biopsy needle. Post-procedure venogram was performed to assess for contrast extravasation indicating capsule perforation or communication with the collecting system. Patients were followed for procedure-related complications. Mean weight was 128 kg (range: 77-187 kg) and body mass index was 44 kg/m(2) (range: 34-64 kg/m(2)). Mean creatinine was 2.2 mg/dl (range: 0.5-6.5 mg/dl). Fifteen patients had diabetes, five of whom were nephrotic; 10 other patients had nephrotic range proteinuria.
RESULTS: Of the 37 patients, six were hospitalized at the time of biopsy and three were admitted for observation. All patients returned to baseline activity the day following procedure. Histopathological diagnosis was made in 33 cases (89.2%) with a mean of 19.2 glomeruli (range: 0-62 glomeruli) per patient. There was one major complication: a delayed retroperitoneal bleed requiring multiple transfusions. Contrast extravasation outside the capsule occurred in five patients and extravasation into the collecting system occurred in three. Body mass index was not associated with number of glomeruli obtained or complication rate.
CONCLUSIONS: TJKB in obese patients is a relatively safe, reliable and minimally invasive procedure with an excellent diagnostic yield.

Entities:  

Mesh:

Year:  2004        PMID: 15128881     DOI: 10.1093/ndt/gfh246

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

Review 1.  Optimizing care for the obese patient in interventional radiology.

Authors:  Dwight Aberle; Hearns Charles; Steven Hodak; Daniel O'Neill; Rahmi Oklu; Amy R Deipolyi
Journal:  Diagn Interv Radiol       Date:  2017 Mar-Apr       Impact factor: 2.630

Review 2.  Complications of transjugular biopsies.

Authors:  Rakesh Navuluri; Osman Ahmed
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

Review 3.  Renal biopsy: Still a landmark for the nephrologist.

Authors:  Luca Visconti; Valeria Cernaro; Carlo Alberto Ricciardi; Viviana Lacava; Vincenzo Pellicanò; Antonio Lacquaniti; Michele Buemi; Domenico Santoro
Journal:  World J Nephrol       Date:  2016-07-06

Review 4.  Renal biopsy practice: What is the gold standard?

Authors:  Soumeya Brachemi; Guillaume Bollée
Journal:  World J Nephrol       Date:  2014-11-06

Review 5.  Technical challenges of imaging & image-guided interventions in obese patients.

Authors:  Raul N Uppot
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

6.  A new method of kidney biopsy using low dose CT-guidance with coaxial trocar and bard biopsy gun.

Authors:  Xiao-Ling Pi; Zhen Tang; Li-Qian Fu; Mei-Hua Guo; Mei-Hua Shi; Lan Chen; Zheng-Ying Wan
Journal:  Biol Proced Online       Date:  2013-01-07       Impact factor: 3.244

7.  Safety and effectiveness of transjugular renal biopsy: A single center study.

Authors:  K R Rathod; B A Popat; A Pandey; T E Jamale; N K Hase; H L Deshmukh
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr

8.  Kidney biopsy guidebook 2020 in Japan.

Authors:  Yoshifumi Ubara; Takehiko Kawaguchi; Tasuku Nagasawa; Kenichiro Miura; Takayuki Katsuno; Takashi Morikawa; Eiji Ishikawa; Masao Ogura; Hideki Matsumura; Ryota Kurayama; Shinsuke Matsumoto; Yuhji Marui; Shigeo Hara; Shoichi Maruyama; Ichiei Narita; Hirokazu Okada; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2021-04       Impact factor: 2.801

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.